Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users
Authors' conclusion
A subgroup of well-controlled twice-daily U-100G users transitioning to degludec benefited from a 50% bridging dose of evening U-100G with the first dose of degludec in a small pilot study.
Study context
- Population
- Patients with T1D on a stable U-100G regimen, HbA1c <75 mmol/mol, transitioning from glargine to degludec; 65% male, mean age 47 years, T1D duration 22 years, BMI 26 kg/m², HbA1c 51 mmol/mol37 completed
- Participants
- 40 patients
- Comparison
- Bridging dose of U-100G vs placebo with first dose of degludec
- Bridgingn = 19
- Placebon = 18reference
- Primary endpoint
- Change in TIR (CGM), 48 h after vs 48 h before transition
- Follow-up
- 48 h before and after transition
Methodological detailsdouble-blind, placebo-controlled, pilot study
- Double-blind
- Placebo-controlled
- Pilot study
Primary result
As reported in the abstract
Change in TIR · 48 h after vs 48 h before transition
- Change in time in range (TIR) not significantly different between the two treatment groups
- Between Bridging and Placebo: not significantly different
Further findings
| Outcome | Bridging | Placebo | P value |
|---|---|---|---|
| Change in TIR (3.9-10 mmol/L), twice-daily U-100G users · 48 h after vs preceding 48 hTIR increased with Bridging, decreased with Placebo | 8% | 9.5% decrease | P = 0.027 |
- Change in TIR (3.9-10 mmol/L), twice-daily U-100G users: Bridging n = 7; Placebo n = 6
Original publication
Bridging dose of U‐100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice‐daily glargine users. Diabetes Obes Metab. Published 28 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →